Asymmetric Reporting of Harms and Benefits in Randomized Controlled Trials
J Gen Intern Med
.
2022 Jun;37(8):2113-2115.
doi: 10.1007/s11606-021-07056-1.
Epub 2021 Aug 11.
Authors
Rubaya Yeahia
1
,
Renee L Gennarelli
2
,
Daniel J Morgan
3
,
Deborah Korenstein
4
5
Affiliations
1
New York Medical College, Valhalla, NY, USA.
2
Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
4
Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[email protected]
.
5
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[email protected]
.
PMID:
34379278
PMCID:
PMC9198137
DOI:
10.1007/s11606-021-07056-1
No abstract available
Publication types
Research Support, N.I.H., Extramural
MeSH terms
Adverse Drug Reaction Reporting Systems*
Humans
Randomized Controlled Trials as Topic
Research Design*
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States